Weight loss field ex­pands as Pfiz­er's oral GLP-1 gath­ers com­par­isons to Novo's We­govy in PhII da­ta

Pfiz­er’s at­tempt to catch up in the weight loss mar­ket picked up steam on Mon­day with re­search show­ing the com­pa­ny’s GLP-1 ag­o­nist helped peo­ple with type 2 di­a­betes shed weight.

With da­ta pub­lished in the JA­MA net­work, led by Pfiz­er VP Adi­ti Sax­e­na, the Big Phar­ma took a step clos­er to stak­ing its spot in the bur­geon­ing R&D field for obe­si­ty drugs, many of which start­ed as di­a­betes meds, and are tout­ed as be­com­ing the biggest drug class in his­to­ry with more than $100 bil­lion on the line.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER